Tehran University of Medical Sciences Journal of Pharmacoeconomics and Pharmaceutical Management 2383-4498 11 03 2026 10 02 4 8 Ashish Danane MIMER Medical College, Talegaon Dabhade Aparna Chincholkar MIMER Medical College, Talegaon Dabhade Ganesh Pentewar MIMER Medical College, Talegaon Dabhade 2025 10 14 2026 03 16 Background: ACE-Inhibitors are commonly used to treat hypertension which is a chronic disorder requiring life-long treatment. There are numerous brands of ACE-Inhibitors available in the Indian pharmaceutical market. There is huge cost variation among different brands of ACE-Inhibitors hence the present study. Methods: Cost of all ACE-Inhibitors (tablets/capsules) available in India was obtained per unit from http://www.medguideindia.com between May to July 2025. For each formulation percentage price variation, mode price and cost ratio were calculated and analysed. Results: Among all ACE-Inhibitors, the highest percentage of price variation and cost ratio was seen in tablet Lisinopril 5mg of 4731.8% and 48.31% respectively, followed by tablet Enalapril maleate 5mg with price variation of 1214.28% and cost ratio of 13.14%. Furthermore, Ramipril 5mg tablet with percentage of price variation and cost ratio of 1098% and 11.98% respectively. Conclusion: There is a lot of price variation among the various brands of ACE-Inhibitors available in India. This can lead to noncompliance by the patient. The regulatory authorities should use their jurisdiction in controlling the price variation of such branded drugs. https://jppm.tums.ac.ir/index.php/jppm/article/view/266